Obinutuzumab, acalabrutinib, and venetoclax, after an optional debulking with bendamustine in relapsed or refractory chronic lymphocytic leukaemia (CLL2-BAAG): a multicentre, open-label, phase 2 trial
Titel:
Obinutuzumab, acalabrutinib, and venetoclax, after an optional debulking with bendamustine in relapsed or refractory chronic lymphocytic leukaemia (CLL2-BAAG): a multicentre, open-label, phase 2 trial
Auteur:
Cramer, Paula Fürstenau, Moritz Robrecht, Sandra Giza, Adam Zhang, Can Fink, Anna-Maria Fischer, Kirsten Langerbeins, Petra Al-Sawaf, Othman Tausch, Eugen Schneider, Christof Schetelig, Johannes Dreger, Peter Böttcher, Sebastian Kreuzer, Karl-Anton Schilhabel, Anke Ritgen, Matthias Brüggemann, Monika Kneba, Michael Stilgenbauer, Stephan Eichhorst, Barbara Hallek, Michael